Profile data is unavailable for this security.
About the company
Bio-Techne Corporation is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities. The Company's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.
- Revenue in USD (TTM)1.17bn
- Net income in USD150.68m
- Incorporated1981
- Employees3.10k
- LocationBio-Techne Corp614 MCKINLEY PL N EMINNEAPOLIS 55413United StatesUSA
- Phone+1 (612) 379-8854
- Fax+1 (612) 656-4400
- Websitehttps://www.bio-techne.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tempus AI Inc | 640.44m | -800.71m | 9.16bn | 2.30k | -- | 168.11 | -- | 14.30 | -8.29 | -8.29 | 4.44 | 0.3459 | -- | -- | -- | -- | -- | -- | -- | -- | 53.18 | -- | -116.06 | -- | 2.55 | -14.95 | 0.891 | -- | 65.85 | -- | 20.35 | -- | -- | -- |
| Revolution Medicines Inc | 742.00k | -567.06m | 9.60bn | 490.00 | -- | 6.11 | -- | 12,938.38 | -3.59 | -3.59 | 0.0047 | 9.34 | 0.0005 | -- | 4.80 | 1,962.96 | -41.28 | -29.76 | -44.46 | -32.59 | -- | -- | -76,423.31 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.06bn | 413.08m | 9.61bn | 20.00k | 23.46 | 2.54 | 12.51 | 2.37 | 8.01 | 8.01 | 78.63 | 73.97 | 0.5203 | 8.27 | 5.23 | 203,045.80 | 5.48 | 6.46 | 6.33 | 7.62 | 35.93 | 36.99 | 10.54 | 11.58 | 1.14 | 4.96 | 0.3784 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Exact Sciences Corp | 2.69bn | -214.04m | 9.75bn | 6.50k | -- | 3.04 | 5,350.26 | 3.62 | -1.17 | -1.17 | 14.70 | 17.35 | 0.4089 | 5.40 | 11.60 | 414,204.30 | -3.25 | -9.71 | -3.58 | -10.60 | 72.96 | 74.10 | -7.95 | -28.21 | 1.93 | -- | 0.4459 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| Exelixis Inc | 2.08bn | 466.92m | 9.90bn | 1.31k | 22.08 | 4.35 | 20.01 | 4.75 | 1.57 | 1.57 | 6.92 | 7.96 | 0.7012 | 3.39 | 8.04 | 1,589,006.00 | 15.73 | 8.86 | 18.08 | 9.91 | 96.25 | 96.30 | 22.43 | 15.43 | 3.88 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Medpace Holdings Inc | 2.07bn | 365.57m | 10.14bn | 5.90k | 28.55 | 11.47 | 25.70 | 4.89 | 11.42 | 11.42 | 64.70 | 28.42 | 1.16 | -- | 6.85 | 350,994.30 | 20.48 | 13.94 | 43.51 | 23.18 | 29.69 | 28.84 | 17.66 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Sarepta Therapeutics Inc | 1.64bn | 121.85m | 10.59bn | 1.31k | 91.16 | 8.67 | 65.98 | 6.46 | 1.22 | 1.22 | 16.30 | 12.79 | 0.489 | 0.5703 | 4.35 | 1,248,362.00 | 3.63 | -21.63 | 4.38 | -25.75 | 85.92 | 86.65 | 7.43 | -77.05 | 3.03 | -- | 0.5013 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
| Vaxcyte Inc | 0.00 | -507.65m | 10.71bn | 254.00 | -- | 3.13 | -- | -- | -4.55 | -4.55 | 0.00 | 27.47 | 0.00 | -- | -- | 0.00 | -20.08 | -34.22 | -20.95 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| BIO-TECHNE Corp | 1.17bn | 150.68m | 10.92bn | 3.10k | 73.09 | 5.11 | 41.67 | 9.32 | 0.9402 | 0.9402 | 7.29 | 13.46 | 0.4267 | 2.15 | 5.47 | 377,930.00 | 5.49 | 9.42 | 5.77 | 10.04 | 65.93 | 67.29 | 12.86 | 21.41 | 3.26 | 18.07 | 0.123 | 22.79 | 1.97 | 10.17 | -41.07 | 11.86 | 19.87 | 0.00 |
| Neurocrine Biosciences, Inc. | 2.24bn | 385.90m | 12.48bn | 1.70k | 33.02 | 4.59 | 30.33 | 5.57 | 3.73 | 3.73 | 21.67 | 26.87 | 0.7027 | 0.8901 | 4.99 | 1,602,000.00 | 12.09 | 9.77 | 14.67 | 12.19 | 98.52 | 98.51 | 17.21 | 14.79 | 4.26 | 10.28 | 0.00 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| Insmed Inc | 342.96m | -864.29m | 13.00bn | 912.00 | -- | 26.89 | -- | 37.91 | -5.56 | -5.56 | 2.21 | 2.70 | 0.2031 | 0.8848 | 8.81 | 376,050.40 | -51.17 | -40.96 | -59.16 | -46.88 | 77.25 | 77.99 | -252.01 | -212.92 | 5.99 | -18.41 | 0.6702 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
| Summit Therapeutics Inc | 0.00 | -196.68m | 13.73bn | 105.00 | -- | 31.34 | -- | -- | -0.2768 | -0.2768 | 0.00 | 0.5941 | 0.00 | -- | -- | 0.00 | -54.53 | -77.32 | -71.71 | -86.35 | -- | -- | -- | -20,989.46 | -- | -- | 0.053 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Moderna Inc | 5.08bn | -2.22bn | 14.22bn | 5.60k | -- | 1.19 | -- | 2.80 | -5.81 | -5.81 | 13.14 | 30.98 | 0.2883 | 2.44 | 2.96 | 907,321.40 | -12.62 | 20.95 | -15.52 | 29.51 | 78.43 | -- | -43.77 | 32.10 | 4.20 | -- | 0.0521 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
Data as of Nov 21 2024. Currency figures normalised to Bio-Techne Corp's reporting currency: US Dollar USD
40.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 17.63m | 11.11% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 9.25m | 5.83% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 9.20m | 5.80% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 6.40m | 4.03% |
| BAMCO, Inc.as of 30 Sep 2024 | 4.45m | 2.80% |
| Geode Capital Management LLCas of 30 Sep 2024 | 3.90m | 2.46% |
| Neuberger Berman Investment Advisers LLCas of 30 Sep 2024 | 3.52m | 2.22% |
| D. F. Dent & Co., Inc.as of 30 Sep 2024 | 3.30m | 2.08% |
| Atlanta Capital Management Co. LLCas of 30 Sep 2024 | 2.99m | 1.88% |
| Mackenzie Financial Corp.as of 30 Sep 2024 | 2.85m | 1.80% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
